喉癌NM23-H1蛋白/核苷二磷酸激酶A表达的研究

运用免疫组化Ｓ－Ｐ法检测喉鳞癌组织中ｎｍ２３－Ｈ１单克隆抗体的表达，结果发现：喉癌组织中ｎｍ２３－Ｈ１蛋白表达阳性率为７２．９％。ｎｍ２３－Ｈ１蛋白表达率在伴有颈洒巴结转移的喉癌中低于无颈淋巴结转移喉癌；在Ⅲ－Ⅳ期喉癌中亦低于Ⅰ－Ⅱ期喉癌。ｍ２３－Ｈ１蛋白民喉癌的生长部位和病理分级无关。结合随访分析分析表明：ｎｍ２３－Ｈ１蛋白表达阳性患者总体生存离高地阴性表达者。提示ｎｍ２３－Ｈ１基因可能有抑制癌

Study on expression of nm23-H_1 protein/NDPK-Ain laryngeal carcinoma

To investigate the expression of nm23-H1 gene in laryngeal squamous cell carcinoma, immunohistochemistry was carried out with a monoclonal antibody against nm23-H1. Of 48 cancer tissues tested, 35(72.9%) showed a positive immuno-reaction for nm23-H1. The percentage of nm23-H1 positivity was significantly lower (P < 0.01) in the tumors with cervical lymph node metastasis than in those without metastasis. Moreover, the percentage of nm23-H1 positivity was significantly lower (P < 0.05) in tumors of stages III-IV than in those of stages I-II. No significant correlation was found between nm23-H1 expression and tumor sites or histopathological grades. Analyzed with following up date, we found that the overall survival was better (P < 0.01) in patients with nm23-H1 expression than in those without expression. These results suggest that nm23-H1 gene may play a role in the suppression of lymph node metastasis and tumor progression in laryngeal carcinoma, and the expression of nm23-H1 gene is a useful predictor of prognosis.